Clinigen collaborates with Servier to expand access to specialised oncology and haematology medicines in South Africa
March 17, 2025 – Drug Delivery, Other, Pharmaceutical – Clinigen, Servier, cardiology, haematology, oncology
17 March 2025 — London, UK — Clinigen, the global speciality pharmaceutical services group, today announced that Equity Pharmaceuticals, part of the Clinigen Group, has entered into a new collaboration with Servier, an independent global pharmaceutical group, to enhance patient access to oncology and haematology medicines in South Africa. Through this new agreement, Clinigen holds exclusive distribution rights to commercialise LONSURF® (trifluridine/tipiracil) in the South African market.
Colorectal cancer (CRC) is the fourth most common and sixth most lethal cancer in South Africa, and approximately 25% of patients are diagnosed with metastatic disease at the time of their primary CRC diagnosis. LONSURF® is indicated for the treatment of advanced colorectal cancer after prior chemotherapy, and advanced gastric cancer after two or more prior treatments.
As part of this agreement, Clinigen will also explore ways of improving patient access to Servier’s wider oncology product portfolio through authorised channels, such as named patient supply or special access programs, in compliance with local regulations.
With Servier’s focused portfolio in difficult-to-treat cancers, Clinigen will enhance the oncology armamentarium for local healthcare professionals to manage increasingly complex oncology cases.
Carel Bouwer, Managing Director at Clinigen Africa says, “Our partnership with Servier is a major leap forward in Clinigen Africa’s mission to accelerate access to oncology therapies across Africa. With Servier’s advanced portfolio, we aim to continue our corporate goal of improving the outcomes and lives of patients.”
Pierre Perez, Managing Director Southern and Eastern Africa at Servier adds, “By joining forces with Clinigen, we are demonstrating our deep commitment to expanding access to our oncology and haematology portfolio across Africa. Their pharmaceutical services’ expertise, combined with our specialised oncology products, creates a powerful synergy to benefit patients.”
This agreement underscores Clinigen’s commitment to providing specialised, integrated pharmaceutical services across the entire drug lifecycle, reinforcing its vision of a world where medicine is global by design. Recent acquisitions and investments, including Ascenian Consulting and Kinesys Consulting, enhance expertise in high-demand areas like Market Access and Regulatory Affairs, while the strategic partnership/minority stake in Tepsivo, a leading digital pharmacovigilance provider, strengthens its competitive advantage in the rapidly growing pharma services market.
This press release contains information about medicines that may not be approved in all territories. The intent of this press release is to share pertinent information for the investment community about this collaboration between Clinigen and Servier and does not constitute promotion of any medicines.
About Clinigen
Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to accelerate access to medicines for patients in every corner of the globe. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa and the Asia Pacific. Clinigen has more than 1,100 employees across five continents in 15 countries and provides access in more than 130 countries every year. For more information on Clinigen, please visit http://www.clinigen.com.
About Servier
Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,900 employees of the Group are committed to this shared vocation, source of inspiration every day. As a world leader in cardiology, Servier’s ambition is to become a focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 70% of its R&D budget to developing targeted and innovative therapies in oncology. Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe and in Brazil. Visit: servier.com/en/servier/
